Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06587685

A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis

This is a Multicenter, Randomized, Double-blind, Placebo-controlled seamless and adaptive-designed phase IIb/III study to Assess the Efficacy and Safety of topical use of PG-011 Gel in adolescents and Adults With Atopic Dermatitis. It consists of phase IIb and phase III parts, phase IIb is a dose-ranging part and has been done, and phase III is a pivotal study part which is registered this time.

The goal of this phase III clinical trial is to learn if PG-011gel works to treat mild to moderate Atopic Dermatitis in adolescents and adults by topical use. It will also learn about the safety of PG-011gel. Investigators will compare PG-011gel to a placebo (a look-alike substance that contains no drug) to see if PG-011gel works to treat mild to moderate Atopic Dermatitis.

Participants will:

* Use PG-011gel or a placebo twice daily for initial 8 weeks, and followed by using PG-011 gel for all of the participants till 52-week. * Visit the clinic at weeks 1, 2, 4 and 8 for checkups and tests, and followed by visiting the clinic every 4 weeks till 52-week. * Keep a diary of their symptoms.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Atopic Dermatitis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

12 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

The First Hospital of China Medical University

Shenyang, Liaoning, China

Location status: Recruiting

Location contact

Xin Hua GAO

CONTACT

[email protected]

+86 13940152467

About this study

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in adolescent and adult participants aged from 12 to 75 years old (including threshold) with mild to moderate Atopic Dermatitis. Approximately 472 participants will be randomized 3:1 to PG-011 gel 3% BID, or placebo gel. In addition, approximately 10% of the overall study population will consist of adolescents. Participants with AD involvement of 3% to 20% BSA and IGA score of 2 to 3 will receive blinded study treatment for 8 weeks followed by an open-label treatment for 44 weeks, at last the safety follow-up for 2 weeks.

The study is to evaluate the efficacy and long-term safety of PG-011 gel 3% in the treatment of mild to moderate Atopic Dermatitis and the PK characteristics by sparse sampling.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 12 years old≤ age ≤ 75 years old (including threshold), male or female.
  • Participants diagnosed of atopic dermatitis (AD) as defined by the Williams diagnostic criteria.
  • AD/eczema duration of at least 1 year for adults and 6 months for adolescents.
  • IGA score of 2 (mild) or 3 (moderate) at the screening day and day 1.
  • %BSA (excluding the scalp) with AD involvement of at least 10% and up to 20%.
  • Willingness to avoid pregnancy or fathering children based on the criteria as outlined in the protocol.

Exclusion criteria

  • Participant has unstable course of AD (spontaneously improving or rapidly deteriorating).
  • Immunocompromised (e.g. lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich syndrome).
  • Any other concomitant skin disorder(e.g. generalized erythroderma, Netherton syndrome, acne, psoriasis, urticaria, pigmentation or extensive scarring）, in the opinion of investigator, may interfere with the evaluation of AD lesions or compromise participant safety.
  • Participant with chronic or acute infection needs to be treated with systemic antibiotics, antiviral drugs, antiparasitic drugs, anti-antigenic animal drugs or antifungal drugs within 2 weeks before randomization.
  • Participant with active acute/chronic bacterial, fungal or viral skin infections (such as herpes simplex, herpes zoster, chickenpox, etc.) before randomization, including but not limited to clinically significant secondary infections of AD or other infections associated with AD lesions.
  • Participant has human immunodeficiency virus (HIV) infection, active hepatitis C virus (HCV) infection (anti-HCV positive), active hepatitis B virus (HBV) infection (HBV-DNA > 2000IU/ml) or Treponema pallidum antibody positive and showing active.
  • Clinically significant or uncontrolled cardiovascular disease (including but not limited to unstable angina, acute myocardial infarction, heart failure, arrhythmia requiring treatment or uncontrolled hypertension).
  • Participant has serious diseases or complications of the central nervous system, respiratory system, liver, kidney, gastrointestinal tract, urinary system, endocrine system or immune system, blood system, etc., and in the opinion of the investigator, may affect the judgment of efficacy and safety .
  • Participant has mental illness such as anxiety disorder, depression, or other conditions that affect the compliance and may interfere with the implementation of clinical research.
  • Participant has a history of malignant tumors before randomization.
  • Participant has severe and uncontrolled disease that may affect safety, trial compliance, affect the evaluation of endpoints, and require the use of drugs that are not allowed in the protocol.
  • Female participant who is lactating or pregnant at the time of screening.
  • Any situation affects the safety and efficacy evaluation of the study drug judged by investigator.
  • Any other condition that, in the opinion of the investigator or sponsor, makes the subject unsuitable for participation in the study.

Treatment and study plan

PG-011Gel

Drug

Twice daily for 52 weeks or 44 weeks

Other names: PG-011Gel 3%

Vehicle

Drug

Vehicle Gel twice daily for 8 weeks

Other names: placebo

Primary outcomes

  1. Proportion of participants who achieved Eczema Area and Severity Index (EASI 75) at Week 8

    Time frame: 8-week

    Defined as ≥ 75% improvement in Eczema Area and Severity Index score. The EASI score ranges from 0 to 72, higher score indicates greater severity.

Secondary outcomes

  1. Key Secondary Outcome: Investigators Global Assessment (IGA) score of 0/1 at Week 8

    Time frame: 8-week

    Proportion of participants achieving Investigators Global Assessment (IGA) score of clear (0) or almost clear (1) with at least a 2-point decrease from baseline at Week 8.

  2. Proportion change of eczema area and severity index (EASI) at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    Proportion change in the eczema area and severity index (EASI) total score from baseline at each scheduled visit. The EASI score ranges from 0 to 72, higher score indicates greater severity.

  3. Change of eczema area and severity index (EASI) score at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    Value change in the eczema area and severity index (EASI) total score from baseline at each scheduled visit. The EASI score ranges from 0 to 72, higher score indicates greater severity.

  4. Change from baseline of Itch Numeric Rating Scale (NRS) at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    The Itch NRS is an assessment tool that participants used to report the intensity of their itch during a 24-hour recall period. The NRS score ranges from 0 to 10 points, higher score indicates greater intensity.

  5. Proportion change from baseline of Child Dermatology Life Quality Index (CDLQI) score at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Child Dermatology Life Quality Index (CDLQI) are designed to measure the impact of any skin disease on the lives of children. The CDLQI score ranges from 0 to 30 points, higher score indicates greater severity.

  6. Change from baseline of Child Dermatology Life Quality Index (CDLQI) score at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Child Dermatology Life Quality Index (CDLQI) are designed to measure the impact of any skin disease on the lives of children. The CDLQI score ranges from 0 to 30 points, higher score indicates greater severity.

  7. Change from baseline of the Patient-oriented eczama Measure (POEM) score at each scheduled visit.

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    The Patient-oriented eczama Measure (POEM) is a comprehensive assessment of the patient own assessment of clinical symptoms in the past week. The POEM score ranges from 0 to 28 points, higher score indicate greater severity.

  8. Proportion change from baseline of affected body surface area (BSA) at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Total body surface area(BSA) is 100%, and the proportion of affected body surface area(BSA) is ranged from 0 to100%, higher value indicates greater severity.

  9. Proportion change from baseline of the Patient-oriented Eczama Measure (POEM) score at each scheduled visit.

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    The Patient-oriented Eczama Measure (POEM) is a comprehensive assessment of the patient own assessment of clinical symptoms in the past week. The POEM score ranges from 0 to 28 points, higher score indicate greater severity.

  10. Proportion change from baseline in Scoring Atopic Dermatitis (SCORAD) score at each scheduled visit.

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Scoring Atopic Dermatitis(SCORAD) is a tool to assess the extent and severity of eczema and will be completed before, during, and after treatment has begun to determine whether the treatment has been effective. The SCORAD score ranges from 0 to 103, and higher score indicates greater severity.

  11. Change from baseline in Scoring Atopic Dermatitis (SCORAD) score at each scheduled visit.

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Scoring Atopic Dermatitis(SCORAD) is a tool to assess the extent and severity of eczema and will be completed before, during, and after treatment has begun to determine whether the treatment has been effective. The SCORAD score ranges from 0 to 103, and higher score indicates greater severity.

  12. Change from baseline of Dermatology Life Quality Index (DLQI) score at each scheduled visit.

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Dermatology Life Quality Index (DLQI) is designed to measure the impact of any skin disease on the lives of adults.The DLQI score ranges from 0 to 30 points, higher score indicates greater severity.

  13. Proportion change from baseline of Dermatology Life Quality Index (DLQI) score at each scheduled visit.

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Dermatology Life Quality Index (DLQI) is designed to measure the impact of any skin disease on the lives of adults.The DLQI score ranges from 0 to 30 points, higher score indicates greater severity.

  14. The average time of the sites achieving Investigators Global Assessment(IGA) 0/1 from baseline

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Average time to achieve Investigators Global Assessment (IGA) score of clear (0) or almost clear (1) by using PG-011gel or a placebo. The IGA score ranges from 0 to 4 points, higher score indicates greater severity.

  15. The average time of the sites achieving Investigators Global Assessment (IGA) 0/1 with at least a 2-point decrease from baseline

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Average time to achieve Investigators Global Assessment (IGA) score of clear (0) or almost clear (1) with at least a 2-point decrease from baseline by using PG-011gel or a placebo. The IGA score ranges from 0 to 4 points, higher score indicates greater severity.

  16. Proportion of achieving Investigators Global Assessment (IGA) 0/1 at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    The IGA score ranges from 0 to 4 points, higher score indicates greater severity.

  17. Proportion of achieving Investigators Global Assessment (IGA) 0/1 with at least a 2-point decrease from baseline at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    The IGA score ranges from 0 to 4 points, higher score indicates greater severity.

  18. The average time of achieving Investigators Global Assessment (IGA) 0/1 at the atopic dermatitis (AD) target site

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    The target site is a representative site of atopic dermatitis skin lesions selected by the investigator. The Investigators Global Assessment (IGA) score ranges from 0 to 4 points, higher score indicates greater severity. The IGA score 0 means clear and IGA score 1 means almost clear.

  19. The average time of achieving Investigators Global Assessment (IGA) 0/1 with at least a 2-point decrease from baseline at the atopic dermatitis (AD) target site

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    The target site is a representative site of atopic dermatitis skin lesions selected by the investigator. The Investigators Global Assessment (IGA) score ranges from 0 to 4 points, higher score indicates greater severity. The IGA score 0 means clear and IGA score 1 means almost clear.

  20. Proportion of participants achieving at least a 3-point decrease of Itch Numeric Rating Scale (NRS) from baseline at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    The Itch NRS is an assessment tool that participants used to report the intensity of their itch during a 24-hour recall period. The Itch Numeric Rating Scale(NRS) score ranges from 0 to 10 points, higher score indicates greater intensity.

  21. Proportion of participants achieving at least a 4-point decrease of Itch Numeric Rating Scale (NRS) from baseline at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    The Itch NRS is an assessment tool that participants used to report the intensity of their itch during a 24-hour recall period. The Itch Numeric Rating Scale(NRS) score ranges from 0 to 10 points, higher score indicates greater intensity.

  22. Change from baseline of affected Body Surface Area (BSA) at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    Total Body Surface Area(BSA) is 100%, and the proportion of affected BSA is ranged from 0 to100%, higher value indicates greater severity.

  23. Proportion of achieving Investigators Global Assessment (IGA) 0/1 in Atopic Dermatitis (AD) target site at each scheduled visit

    Time frame: Week1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

    The target site is a representative site of atopic dermatitis skin lesions selected by the investigator. The Investigators Global Assessment (IGA) score ranges from 0 to 4 points, higher score indicates greater severity. The IGA score 0 means clear and IGA score 1 means almost clear.

  24. Proportion of Investigators Global Assessment (IGA) 0/1 with at least a 2-point decrease from baseline in Atopic Dermatitis (AD) target site at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    The target site is a representative site of atopic dermatitis skin lesions selected by the investigator. The Investigators Global Assessment (IGA) score ranges from 0 to 4 points, higher score indicates greater severity. The IGA score 0 means clear and IGA score 1 means almost clear.

  25. Proportion of participants achieving Eczema Area and Severity Index(EASI) 50 at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    Defined as at least 50% improvement from baseline in Eczema Area and Severity Index(EASI) score at each scheduled visit.The EASI score ranges from 0 to 72, higher score indicates greater severity.

  26. Proportion of participants achieving Eczema Area and Severity Index(EASI) 75 at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    Defined as at least 75% improvement from baseline in Eczema Area and Severity Index(EASI) score at each scheduled visit. The EASI score ranges from 0 to 72, higher score indicates greater severity.

  27. Proportion of participants achieving Eczema Area and Severity Index(EASI) 90 at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    Defined as at least 90% improvement from baseline in Eczema Area and Severity Index(EASI) score at each scheduled visit.The EASI score ranges from 0 to 72, higher score indicates greater severity.

  28. Proportion of participants achieving Eczema Area and Severity Index(EASI) 100 at each scheduled visit

    Time frame: Week 1, 2,4, 8, 12,16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

    Defined as at least 100% improvement from baseline in Eczema Area and Severity Index(EASI) score at each scheduled visit.The EASI score ranges from 0 to 72, higher score indicates greater severity.

Study contacts

Contact information is provided by the study sponsor or research team.

Li Zhang, Professor

CONTACT

[email protected]

Xinghua Gao, Professor

CONTACT

[email protected]

+86-13940152467

Sponsors and collaborators

Lead sponsor

Prime Gene Therapeutics Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of PG-011 Gel With 8 Weeks Treatment and Extension Safety Study to 52 Weeks in Adolescents and Adults With Atopic Dermatitis

Important dates

Study start
2024
Primary completion
2024
Study completion
2026
First posted
Sep 19, 2024
Registry last updated
May 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.